Organon & Co. (NYSE:OGN) Stock Has Consensus Target Price of $11.40

Organon & Co. (NYSE:OGN) has been assigned a consensus recommendation of “Reduce” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $11.40.

Separately, Weiss Ratings cut shares of Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 3rd.

Organon & Co. Stock Down 0.0%

NYSE:OGN opened at $13.72 on Friday. Organon & Co. has a twelve month low of $5.69 and a twelve month high of $13.78. The firm has a market capitalization of $3.60 billion, a price-to-earnings ratio of 17.82, a price-to-earnings-growth ratio of 1.27 and a beta of 1.52. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43. The stock’s 50 day moving average price is $13.66 and its two-hundred day moving average price is $11.96.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 10th. Shareholders of record on Friday, August 14th were given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Friday, August 14th. Organon & Co.’s payout ratio is 10.39%.

Hedge Funds Weigh In On Organon & Co.

Several large investors have recently modified their holdings of OGN. Allied Private Wealth LLC bought a new position in Organon & Co. in the 2nd quarter valued at about $33,000. Eurizon Capital SGR S.p.A. acquired a new position in shares of Organon & Co. in the fourth quarter valued at approximately $44,000. WNY Asset Management LLC bought a new position in shares of Organon & Co. during the first quarter worth approximately $64,000. Wealth Effects LLC bought a new position in shares of Organon & Co. during the first quarter worth approximately $75,000. Finally, Nykredit A S acquired a new stake in Organon & Co. during the 2nd quarter worth approximately $76,000. 77.43% of the stock is owned by institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company focused on improving the health and well-being of women throughout their lives. Its women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as fertility treatments and medicines used in reproductive health.

The company also markets biosimilars and a portfolio of established medicines across areas including cardiovascular disease, respiratory conditions, dermatology, pain management and allergy. Its products are distributed in markets around the world, with a particular focus on expanding access to medicines in international and emerging markets.

Organon was established as an independent company through a spin-off from Merck & Co in June 2021.